A0502383-3883-4EB4-A63B-5586891AD3FC
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.520367936925098
- age_years
- 47
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.543
- DNA_REPAIR+0.389
- E2F_TARGETS+0.370
- WNT_BETA_CATENIN_SIGNALING+0.346
- G2M_CHECKPOINT+0.320
- HEDGEHOG_SIGNALING+0.316
- MYC_TARGETS_V1+0.293
- MITOTIC_SPINDLE+0.269
- CHOLESTEROL_HOMEOSTASIS+0.216
- UNFOLDED_PROTEIN_RESPONSE+0.145
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.419
- ALLOGRAFT_REJECTION-0.418
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.418
- TNFA_SIGNALING_VIA_NFKB-0.404
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- INTERFERON_GAMMA_RESPONSE-0.370
- IL6_JAK_STAT3_SIGNALING-0.353
- COAGULATION-0.342
- ANGIOGENESIS-0.340
- COMPLEMENT-0.334
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6819D9DA-FE18-4584-8AF6-E53DD894852E | — | — | 0.903 |
| 2 | BS_5P1TN10Z | Embryonal tumors | — | 0.883 |
| 3 | 9CC5EB30-A8C2-4FDF-8074-467AA98ED1CA | — | — | 0.882 |
| 4 | A19ADC4B-C7E3-4855-9B59-009865D4FBF0 | — | — | 0.881 |
| 5 | ERR2598195 | fetal | fetal | 0.880 |
| 6 | 10FB7E59-9D71-4AB9-8D06-9CFD2304D1BC | — | — | 0.879 |
| 7 | SRR934951 | — | — | 0.878 |
| 8 | 7DC6D598-8506-4680-81DF-C1D0F1B5C27D | — | — | 0.875 |
| 9 | TCGA-J1-A4AH-01A-31R-A24H-07 | — | cohortSQ2 | 0.873 |
| 10 | CA9E9B92-5D16-4455-ACC8-ACBFDFB754C5 | — | — | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.543 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.389 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.346 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.316 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.293 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.269 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.216 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.145 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.122 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.109 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.012 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.001 | Inavolisib | — uncovered |